Drug intelligence / Profile preview

INN-217

Development stage: Preclinical
Lead developer: Innovate Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

INN-217 is a proprietary oral formulation of the tight junction modulator larazotide being developed to improve delivery to the intestine for gastrointestinal indications such as celiac disease. By optimizing larazotide exposure at the intestinal mucosa while limiting systemic absorption, INN-217 is intended to enhance restoration of epithelial barrier integrity and reduce antigen-driven inflammation in patients with barrier dysfunction–mediated conditions.[5]

Beyond the preview

Go deeper on INN-217.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INN-217.

Explore the full profile